ESMO 2023

Preoperative checkpointinihition in ER+ disease

My highlights of ESMO23 in metastatic breast cancer

5 year follow-up

Highlights in eBC

DATO-DX - where is it going?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Clearing up non-clear cell RCC

When the history of ADC is written: Redefining first-line standard of care in mUC!

New 3rd line therapy for RCC

The FGFR story in bladder cancer at ESMO23

Early use of enzalutamide in advanced prostate cancer

Lu-PSMA leads forward

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

My highlights from ESMO 2023

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

ALINA - immediate change of practice!

Tarlatamab in SCLC

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

What is your definition of triple-negative breast cancer?

Anticipated updates and exciting new data for checkpointinhibitors

New and better biomarkers are needed!

What was the most exciting news at ESMO23?

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

My highlights of ESMO23 in early breast cancer

Detailed view of nodal-negative patients

5 year follow-up

MonarchE - trial update

ER-low corresponds diagnostically to ER-0 breast cancer

Preoperative checkpointinihition in ER+ disease

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Carry-over effects in monarchE confirmed

Analysis of tumour microenvironment and immunophenotype in TNBC

Ribociclib effective in all subtypes

Immunoncology in eBC - triple negative and more?

HR+ study with > 20 % PCR

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Highlights in eBC

Our guidelines are correct

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Consolidation of data in early HR+ and triple-negative breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

Clinically relevant effect of pembro also in PCR

Negative EFS results from NeoTrip

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

New data on neoadjuvant immunotherapy

MonarchE - mise à jour de l'essai

Studio NeoTrip: negativi i risultati

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

Punti salienti in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

New targets, new linker, new ADCs - much more to learn with new therapies!

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

How to organize a molecular tumorboards in breast cancer?

New ADC for metastatic breast cancer?

What was the most exciting news at ESMO23?

Improvement of therapy outcome by app-based patient education

DATO-DX - where is it going?

Can surgery be spared following primary systemic therapy?

Benefit for SG even after intensive pretreatment

T-DXd - new standard of care for brain mets?

Even more new generation ADCs in breast cancer?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Patient-centered molecular medicine - a new approach

Highlights in mBC

OP seems to be dispensable for super responders

HER2DX in the PHERgain trial

Abemaciclib remains consistent in 5-year follow-up

TROP2 expression as a potential mechanism of resistance in HER2+ patients

Improved oncological therapy with the smartphone

HS20089 - a novel ADC is coming for TNBC

T-DXd also effective for brain metastases

TULIP: Trastuzumab duocarmazine without OS benefit

My highlights of ESMO23 in metastatic breast cancer

Fulvestran better than anastrozole, but no survival benefit

T-DXd in HER2+ patients with brain metastases

New ADC in HR+ disease

Dato-DXd - new player in advanced luminal disease

Duvalumab + Dato-DXd effective

ADC + Immunotherapy - the BEGONIA study paradigm

Still on track for success in HER2-low MBC

Our guidelines are correct

Robust data from the monarchE

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

HER2DX en el estudio PHERgain

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Punti salienti in mBC

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

Lo studio BEGONIA nelle paziento con tumore triplo negativo

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Targeted therapy will move forward - but more robust data is needed.

What is the future of immune therapy in prostate cancer?

Should we use zoledronic acid in all ADT patients?

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

EMBARK expands ENZA indication to PCa

RADICALS RT: Trial and controversies

CXCR2 inhibitor in PCa

TITAN: ultra-low PSA = best prognosis

Salvage radiotherapy the new standard

Brave New World in mCRPC

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

Precision medicine at mCRCP

Osteoprotection at mHSPC

PSMA FORE: Trial and controversies

EMBARK - Quality of Life

Embark without fear

Early use of enzalutamide in advanced prostate cancer

Combination of radioligand therapy with chemotherapy useful

Negative data for pembrolizumab in mHSCPC & mCRPC

IO therapy in metastatic prostate cancer.

ENZA P:Trial and controversies

Immunotherapy in metastatic PCa

Lu-PSMA leads forward

PSMAfore unleashes urooncologic opportunity

Longterm toxicity of adjuvant RT after prostatectomy

Big data and AI prediction tools

CXCR2 hämmare och prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

Big Data och AI för prediktion vid prostatacancer

Immunterapi vid prostatacancer

EMBARK och livskvalitet

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part 2: New standard of care in first line urothelial cancer!

Part1: New standard of care in first line urothelial cancer?!

DAD, DAD-IO

Chemo-IO establishes itself in the first-line treatment of bladder cancer

When the history of ADC is written: Redefining first-line standard of care in mUC!

Amazing new data in bladder cancer

FGFR inhibitors: What is the best scenario for this family of compounds?

EV + Pembro as standard of care in first-line therapy of bladder cancer

New SoC in firstline bladder cancer

Unique bladder delivery system of gemcitabine herolds remarkable response

The FGFR story in bladder cancer at ESMO23

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Where does the future therapy go in renal cell carcinoma?

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of patients?

New mode of action in mRCC - ready for prime time?

Kidney cancer highlights at ESMO23

Belzutifan - whats next kidney cancer?

Clearing up non-clear cell RCC

Intermittent therapy also possible with TKIs

Belzutifan in later lines of therapy

New 3rd line therapy for RCC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Substantial improvement in local regional NSCLC

Circulating DNA in AEGEAN trial

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Scene is set for inductive immunotherapy

ALINA - immediate change of practice!

Big improvements in early stage and a subset of metatstic NSCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Perioperative IO: OS-benefi from KEYNOTE-671

My highlights from ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Les points forts de l'ESMO 2023

I miei punti salienti di ESMO 2023

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Activating EGFR-mutation - what's coming up?

Evolving landscape of ADCs

ESMO2023-impact on everyday practice!

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

MARIPOSA II: Trial and controversies

Brain metastases – options to improve the systemic treatment

By unanimous decision and still the champion – docetaxel!

PAPILLON - bringing together therapy for the 1st line

LIBRETO - a positive study, but was it necessary?

My highlights from ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

TROPION-Lung01: positive development

Substantial improvement in rare alterations

Do ADCs have brain activity?

NRG fusions: a new drugable target?

Amivantamab at progression? MARIPOSA-2 trial

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

MARIPOSA: Trial and controversies

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Does immunotherapy still have a place in EGFR-positive mNSCLC?

Practice changing results on exon 20 insertion mNSCLC

Big improvements in early stage and a subset of metatstic NSCLC

Changing treatment landscape in EGFR-mutated NSCLC

Treatment sequences for EGFR-mutated Patients

Amivantamab upfront? MARIPOSA trial

Quelles séquences thérapeutiques pour les patients EGFR mutés

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Les points forts de l'ESMO 2023

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Amivantamab upfront? MARIPOSA trial

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

I miei punti salienti di ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Amivantamab at progression? MARIPOSA-2 trial

Impact of T-cell engagers in SCLC

A new option in relapsed SCLC

New hope for patients with SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

Evolution of the revolution - the RUBY trial

Update on gynaecological cancers

First data on luveltamab in multiline treatment for endometrial cancer

Precision oncology in CUP

New data on H&N Cancer

PCO Therapeutics

New data on sarkomas